Independent health-science reporting · Evidence ratedEvidence rated
Section
Trial openings, protocol designs, endpoint choices, and enrollment realities — including the trials patients and clinicians should know are recruiting now.
A cross-sectional registry analysis shows a marked rise in trials initiated after 2016 and a significant increase in industry sponsorship.
A phase II trial evaluates the activity and safety of a VEGF receptor inhibitor in patients with limited remaining treatment options.
A Phase 2 clinical trial reports survival and surgical resection outcomes for patients receiving the GSRT protocol.
A review paper outlines the key regulatory and quality considerations needed to transition targeted cancer therapies from early clinical trials to commercial-scale production.
The HYPERBOLIC trial evaluates whether adding short-course chemotherapy to cemiplimab mitigates the risk of hyperprogressive disease in biomarker-selected lung cancer patients.
A correction notice has been registered for a phase II trial evaluating neoadjuvant paclitaxel-carboplatin followed by surgery.
